What is Atomic AI?
Atomic AI specializes in AI-driven RNA drug discovery, leveraging advanced machine learning and structural biology to create RNA-targeted small molecules and RNA-based medicines. Their proprietary platform integrates state-of-the-art deep learning models with in-house wet-lab assays to accelerate the identification of potent and selective therapeutics. The company aims to address critical health challenges by developing novel treatments, positioning itself as a key player in the biopharmaceutical innovation landscape. Their target clientele includes pharmaceutical firms and research institutions seeking cutting-edge drug development solutions.
How much funding has Atomic AI raised?
Atomic AI has raised a total of $35M across 1 funding round:
Series A
$35M
Series A (2023): $35M with participation from Playground, 8VC, AME Cloud Ventures, Greylock Partners, and The Factory HQ
Key Investors in Atomic AI
Playground
Playground Global is a venture capital firm that invests in founders utilizing frontier technologies to build transformational businesses, with a focus on AI, life sciences, and next-gen compute.
8VC
8VC is a technology investment firm known for backing visionary teams and industry-transforming companies, with expertise in smart enterprise platforms across various sectors including healthcare and Bio-IT.
AME Cloud Ventures
AME Cloud Ventures, led by Yahoo! co-founder Jerry Yang, focuses on seed to later-stage companies building infrastructure and value chains around data, particularly in technology-heavy sectors.
What's next for Atomic AI?
The recent major enterprise-level funding positions Atomic AI for significant expansion and acceleration of its research and development pipeline. This strategic investment will likely fuel advancements in their AI platform, enabling the discovery and progression of new RNA-based therapeutics. The company is poised to further solidify its market position by addressing unmet medical needs and forging strategic partnerships within the pharmaceutical industry. Continued innovation in their deep learning models and assay capabilities will be crucial for sustained growth and impact in the competitive drug discovery sector.
See full Atomic AI company page
